Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

Takeda Pharmaceutical Company Limited and Natrogen Therapeutics International, Inc. jointly announced today an agreement whereby Takeda will acquire an exclusive license to develop Natrogen's Natura-alpha compound as well as an option to acquire Natrogen. Natura-alpha is a synthetic small molecule oral compound that is believed to inhibit pro-inflammatory cytokine expression, which may help to reduce gastrointestinal inflammation. Natura-alpha is currently in Phase 2 development for the treatment of ulcerative colitis.

20 Dec 2013

AGA guidelines recommend anti-TNF-α biologic agents to induce remission in Crohn's disease patients

The anti-TNF-α biologic agents, such as infliximab or adalimumab, are recommended to induce remission in patients with moderately severe Crohn's disease , according to a new guideline from the American Gastroenterological Association. Additionally, the guidelines recommend against using thiopurines or methotrexate alone to induce remission in these patients. The new guideline and accompanying technical review have been published in Gastroenterology, the official journal of the AGA Institute.

18 Dec 2013

Biogen joins with Samsung Bioepis to commercialize anti-TNF biosimilar product candidates in Europe

Biogen Idec (NASDAQ: BIIB) and Samsung Bioepis today announced that through their joint venture, Biogen Idec has exercised its right to enter into an agreement to commercialize anti-TNF biosimilar product candidates in Europe, including biosimilars for widely used therapies to treat conditions such as rheumatoid arthritis and Crohn's disease.

17 Dec 2013

Broad Medical Research Program, Crohn's & Colitis Foundation of America to merge together

The Broad Medical Research Program, which funds innovative early-stage research into inflammatory bowel disease, will merge with the Crohn's & Colitis Foundation of America, the two organizations announced today.

11 Dec 2013

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States Food and Drug Administration voted to recommend approval of Takeda's vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.

9 Dec 2013

Scientists identify key factor for limiting inflammatory responses, particularly in skin

Sanford-Burnham scientists have identified the B and T Lymphocyte Attenuator (BTLA) inhibitory receptor as a key factor in limiting inflammatory responses, particularly in the skin. The study, published online today in Immunity, provides clarity on how T cells get fired up to protect against pathogens, and then cool down to restore immune homeostasis.

6 Dec 2013

Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.

5 Dec 2013

IDSA released new guideline for vaccination of immunocompromised hosts

A new guideline released Thursday by the Infectious Diseases Society of America (IDSA) notes that most people with compromised immune systems are especially vulnerable to illness and should receive the flu shot and other vaccinations.

5 Dec 2013

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

The exact definition of orphan diseases varies depending on where you are in the world. In the EU it's defined as a prevalence of less than 1 in 2,000, which equates to about 250,000 patients across the EU.

4 Dec 2013

Research findings pave new ways to treat gastrointestinal disorders

For those living with gastrointestinal disorders, such as ulcers or Crohn's disease, treatment often means quelling uncomfortable symptoms through medications or dietary changes. But what if one day treatment meant doing away with the old gut for a new gut free of inflamed or diseased tissues?

4 Dec 2013

Researchers find way to replace Paneth cells with two small molecules that maintain stem cells

Researchers at MIT and Brigham and Women's Hospital have shown that they can grow unlimited quantities of intestinal stem cells, then stimulate them to develop into nearly pure populations of different types of mature intestinal cells. Using these cells, scientists could develop and test new drugs to treat diseases such as ulcerative colitis.

3 Dec 2013

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease.

2 Dec 2013

Immune Pharmaceuticals to transfer common stock listing from NASDAQ OMX Stockholm Exchange

Immune Pharmaceuticals Inc. announced today that its common stock has been approved for trading on NASDAQ OMX First North Premier, Stockholm ("First North").

26 Nov 2013

Keeping active reduces women’s Crohn’s risk

Regular exercise protects women against the development of Crohn’s disease, reveals research published in the BMJ.

21 Nov 2013

Scientists receive $2.2M grant to improve treatments for immune disorders, inflammatory diseases

Scientists from the Walter and Eliza Hall Institute have been awarded more than $2.2 million from the Australian Research Council (ARC) to improve treatments for immune disorders and inflammatory diseases.

16 Nov 2013

Antibe Founder and Chief Science Officer honored with Heymans Foundation Memorial Medal

Antibe Therapeutics Inc. is proud to announce that Dr. John Wallace, the Corporation's Founder and Chief Science Officer, was awarded the Heymans Foundation Memorial Medal in Ghent, Belgium, today.

8 Nov 2013

Four-year study to develop targeted approach to psoriasis treatment

A world-leading taskforce led by The University of Manchester has begun work to create a new test to help medics work out which treatment plan is most likely to improve the disabling skin condition psoriasis, based on a patient's individual biological make-up.

8 Nov 2013

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

AGA guidelines recommend anti-TNF-α biologic agents to induce remission in Crohn's disease patients

Biogen joins with Samsung Bioepis to commercialize anti-TNF biosimilar product candidates in Europe

Broad Medical Research Program, Crohn's & Colitis Foundation of America to merge together

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Scientists identify key factor for limiting inflammatory responses, particularly in skin

Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

IDSA released new guideline for vaccination of immunocompromised hosts

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

Research findings pave new ways to treat gastrointestinal disorders

Researchers find way to replace Paneth cells with two small molecules that maintain stem cells

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Immune Pharmaceuticals to transfer common stock listing from NASDAQ OMX Stockholm Exchange

Keeping active reduces women’s Crohn’s risk

Scientists receive $2.2M grant to improve treatments for immune disorders, inflammatory diseases

Antibe Founder and Chief Science Officer honored with Heymans Foundation Memorial Medal

Four-year study to develop targeted approach to psoriasis treatment

Researchers identify new class of anti-inflammatory drugs may be used to treat IBD

Leukemia drug reverses symptoms of colitis in lab tests

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in